Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Dose Escalation and Dose Expansion Study of NPX887 in Participants With Solid Tumor Malignancies Known to Express B7-H7/HHLA2
Conditions
Interventions
NPX887
Locations
8
United States
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, United States
Albert Einstein Medical College Montefiore Medical Center
The Bronx, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
Next Oncology
San Antonio, Texas, United States
NEXT Oncology-Fairfax
Fairfax, Virginia, United States
Start Date
January 22, 2024
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
June 27, 2025
NCT04988009
NCT03270059
NCT05235165
NCT05753306
NCT04870944
NCT04489719
Lead Sponsor
NextPoint Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions